Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 plus neoadjuvant chemotherapy versus chemotherapy alone in stage III non-small cell lung cancer
ChiCTR2000037950Phase 4Recruiting
- Sponsor
- Gansu Cancer Hospital
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (2 arms), sponsored by Gansu Cancer Hospital. Primary endpoints: Objective response rate, Surgical rate after downstaging and 1 more. Started May 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2000037950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037950.